Acanthosis nigricans
☆ AI Dermatology — Free Service
I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
Tá sé coitianta i ndaoine murtacha.
relevance score : -100.0%
ReferencesIs léiriú cutáinis de riocht bunúsach é Acanthosis nigricans (Acanthosis nigricans). Is minic a bhíonn sé le feiceáil i bhfillteacha craicinn cosúil leis an muineál, na fuinneoga, agus an glúin, mar pháirteanna dorcha, velvety, le imill neamhshainmhínithe. Tá an coinníoll seo nasctha de ghnáth le diaibéiteas agus friotaíocht inslín, ach i gcásanna neamhchoitianta, d'fhéadfadh sé a bheith comhartha de ailse inmheánach sa chorp. D'fhéadfadh sé a thaispeáint freisin mar gheall ar shaincheisteanna hormóin nó ó ghlacadh míochán ar leith cosúil le glucocorticoids córais agus píosaí rialaithe breithe.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Is riocht craiceann coitianta é Acanthosis nigricans (AN) atá nasctha le saincheisteanna sláinte éagsúla cosúil le frithsheasmhacht inslin, diaibéiteas, murtall, cógais áirithe, fadhbanna hormónacha, agus frithghníomhartha ar chógais. Díríonn cóireáil AN ar aghaidh a thabhairt ar na bunfhadhbanna sláinte. Ar dtús, déanann dochtúirí seiceáil le haghaidh comharthaí de shiondróm frithsheasmhachta inslin, lena n-áirítear obais, colaistéaról ard, brú fola ard, agus diaibéiteas cineál 2. Is minic a fhorordaíonn dochtúirí topical retinoids mar an chéad rogha cóireála, rud a d'fhéadfadh cabhrú le ramhrú craiceann. Mar sin féin, ní fhéadfaidh siad dul i ngleic go hiomlán le dorchadas craiceann. Ní mór roghanna cóireála eile (salicylic acid, podophyllin, urea, calcipotriol) a chur i bhfeidhm go minic freisin.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Cúis
Tarlaíonn sé go hiondúil i ndaoine níos óige ná 40 bliain d’aois, d’fhéadfadh sé a bheith le hoidhreacht ghéiniteach agus tá baint aige le obesity (obesity) nó endocrinopathies (endocrinopathies), mar hypothyroidism (hypothyroidism), acromegaly, polycystic ovary disease (polycystic ovary disease), insulin‑resistant diabetes (insulin‑resistant diabetes) nó galar Cushing.
○ Cóireáil - Drugaí OTC
#40% urea cream